Biogen Inc
BIIB: XNAS (USA)
Morningstar Rating for Stocks | Fair Value | Economic Moat | Capital Allocation |
---|---|---|---|
$273.00 | Hxln | Wzrnnsql |
Launches in Alzheimer's and Depression Support Biogen's Neurology-Based Wide Moat
Business Strategy and Outlook
We think Biogen's specialty-market-focused drug portfolio and novel, neurology-focused pipeline create a wide moat. Biogen's strategy has its roots in the 2003 merger of Biogen (multiple sclerosis drug Avonex) and Idec (cancer drug Rituxan). While Rituxan is succumbing to biosimilar competition, Biogen is expanding its neurology portfolio beyond MS, including blockbuster neuromuscular disease drug Spinraza and several promising drugs, including Leqembi in Alzheimer's disease.